

**AMENDMENTS TO THE SPECIFICATION**

**After the title and before the section entitled "Field of the Invention" please insert the following sentence:**

This application is a national stage application, filed under 35 U.S.C. § 371, of International Application No. PCT/IB03/00332, filed September 1, 2003, and which claims priority to U.S. Provisional Application No. 60/347062, filed September 1, 2002, all of which are hereby incorporated by reference.

**Please delete the paragraphs on page 17, lines 5-25 and replace them with the following paragraphs:**

The TAT sequence may be linked either to the N-terminal or the C-terminal end of the SH3 binding peptide. A hinge of two proline residues may be added between the TAT and SH3 binding peptide to create the full fusion peptide. For example, amino acid fusion peptides may be the TAT- $\alpha$ SH3 peptide (SEQ ID NO: 3) or the generic TAT- $\alpha$ SH3 peptide (SEQ ID NO: 4). Retro-inverso fusion peptides may be the RV-TAT- $\alpha$ SH3 peptide (SEQ ID NO: 20) or the generic RV-TAT- $\alpha$ SH3 peptide (SEQ ID NO: 21). The TAT peptide may be a retro-inverso peptide having the sequence  $\text{NH}_2[[-X_n]]\text{-RRRQRRKKR-}[[X_n]]\text{COOH}$  (SEQ ID NO: 38) or the TAT-peptide can be a generic retro-inverso peptide having the sequence  $\text{NH}_2\text{-X}_n\text{-RRRQRRKKR-X}_n\text{-COOH}$  (SEQ ID NO: 39). In SEQ ID NO: 3-4 and 38-39, the number of "X" residues is not limited to the one depicted nor is the number of Xs in a given peptide limited to the one depicted, and accordingly, the "X" residues may vary as described above. The fusion peptide can include one or more of the SH3-BPs of SEQ ID NO: 1-35. For example, the fusion peptide can be a chimeric peptide comprising the sequence of SEQ ID NO: 36 covalently linked to the sequence of SEQ ID NO: 7, or alternatively the chimeric peptide can comprise the sequence of SEQ ID NO: 38 covalently linked to the sequence of SEQ ID NO: 24. For example,

the fusion peptide can include a chimeric peptide comprising the sequence of SEQ ID NO: 36 covalently linked to a sequence selected from SEQ ID NO: 7-17, or alternatively, the chimeric peptide can comprise the sequence of SEQ ID NO: 38 covalently linked to an amino acid sequence selected from the group consisting of SEQ ID NO: 24-34. Any combination of SH3 binding peptides and trafficking sequences are within the scope of the present invention.